Clinical & Translational

The company attributed its third quarter revenue decline to bad weather.

The firm signed deals with a US hospital and a European reference lab for the T2Dx platform and T2 Candida sepsis test.

The firm brought in total revenues of $68.2 million for the three months ended March 31, up from $67 million in the first quarter of 2014 but below the consensus Wall Street estimate of $69.9 million.

The collaboration will leverage NanoString's nCounter Analysis System and PanCancer Immune Profiling technology in multiple prospective CITN clinical trials.

On an adjusted basis and at constant exchange rates, revenues increased 2 percent year over year, led by consumables and instrument revenues across all customer classes.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.